Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Integration of Targeted Gene Expression Profiling and FDG-PET Radiomics Uncovers Radiometabolic Signatures Associated with Outcome in Diffuse Large B-Cell Lymphoma

Saveria Mazzara, Laura L. Travaini, Francesca Botta, Chiara Granata, Giovanna Motta, Federica Melle, Stefano Fiori, Valentina Tabanelli, Anna Vanazzi, Safaa M. Ramadan, Tommaso Radice, Sara Raimondi, Giuliana Lo Presti, Mahila E. Ferrari, Marta Cremonesi, Francesco Ceci, Corrado Tarella, Stefano A Pileri, Enrico Derenzini

Blood (2021) 138 (Supplement 1): 3496.

https://doi.org/10.1182/blood-2021-152679

Published: 2021

Journal Articles

Follicular Lymphoma Microenvironment Signatures Define Patients Subsets Obtaining Long Term Clinical Benefit after Single-Agent First-Line Anti-CD20 Immunotherapy

Enrico Derenzini, Marcello Del Corvo, Maria Chiara Quattrocchi, Marta Castelli, Maria Rosaria Sapienza, Saveria Mazzara, Stefano Fiori, Anna Vanazzi, Safaa M. Ramadan, Stefano A Pileri, Corrado Tarella

Blood (2021) 138 (Supplement 1): 3500.

https://doi.org/10.1182/blood-2021-153778

Published: 2021

Journal Articles

B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in18 Consecutive Patients from Two Italian Institutions

Safaa M. Ramadan, PhD MD, Alessandro Cignetti, MD PhD, Simona Sammassimo, MD, Enrico Derenzini, MD PhD, Giusy Ceparano, MD, Tommaso Radice, MD, Federica Gigli, MD, Stefano Fiori, MD, Valentina Tabanelli, MD, Martina Milani, Emanuela Omodeo Sale', Sara Gandini, PhD, Daniela Gottardi, MD, Giuseppe Saglio, MD, Stefano Pileri, MD, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 1631.

https://doi.org/10.1182/blood-2019-128794

Published: 2019

Journal Articles

Prognostic Impact of the Baseline Immunologic Profile in Patients with Aggressive B Non-Hodgkin Lymphomas

Safaa M. Ramadan, PhD MD, Giusy Ceparano, MD, Alessandro Cignetti, MD PhD, Simona Sammassimo, MD, Vincenzo Bagnardi, Eleonora Pagan, Daniela Gottardi, MD, Stefano Fiori, MD, Rita Passerini, Tommaso Radice, MD, Giuseppe Saglio, MD, Corrado Tarella, MD

Blood (2019) 134 (Supplement_1): 1522.

https://doi.org/10.1182/blood-2019-132237

Published: 2019

Journal Articles

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Dominik L.D. Selleslag, MD, Stefan Suciu, Giovanna Meloni, MD, Petra Muus, MD PhD, Constantijn J.M. Halkes, MD PhD, Adriano Venditti, MD, Safaa M Ramadan, MD PhD, Hans Pruijt, MD PhD, Liv Meert, MSc, Marco Vignetti, MD, Jean-Pierre Marie, MD, Dominique Bron, MD PhD, Theo de Witte, MD, Sergio Amadori, MD, Roelof Willemze, MD PhD, Frederic Baron, MD PhD

Blood (2014) 124 (21): 3675.

https://doi.org/10.1182/blood.V124.21.3675.3675

Published: 2014

Journal Articles

Improved Overall Survival with Gemtuzumab Ozogamicin (GO) Compared with Best Supportive Care (BSC) in Elderly Patients with Untreated Acute Myeloid Leukemia (AML) Not Considered Fit for Intensive Chemotherapy: Final Results from the Randomized Phase III Study (AML-19) of the EORTC and Gimema Leukemia Groups

Blood (2014) 124 (21): 619.

https://doi.org/10.1182/blood.V124.21.619.619

Published: 2014

Journal Articles

Survival Improvement Of Secondary Acute Myeloid Leukemia Over Time: Experience From 962 Patients Included In 13 EORTC-Gimema-HOVON Leukemia Group Trials

Safaa M. Ramadan, MD, PhD, Stefan Suciu, PhD, Marian J.P.L. Stevens-Kroef, PhD, Roelof Willemze, MD, PhD, Sergio Amadori, Theo de Witte, MD, Bob Lowenberg, MD, PhD, Petra Muus, MD, PhD, Boris Labar, MD, PhD, Liv Meert, Gaetan de Schaetzen, Giovanna Meloni, MD, Giuseppe Leone, MD, Marco Vignetti, Franco Mandelli, MD, Frederic Baron, MD, PhD, Jean-Pierre Marie, MD

Blood (2013) 122 (21): 829.

https://doi.org/10.1182/blood.V122.21.829.829

Published: 2013

Journal Articles

Treatment of Molecular and Clinical Relapse of Acute Promyelocytic Leukemia (APL) with Arsenic Trioxide: Results of the European Registry of Relapsed APL

Eva Lengfelder, MD, PhD, Francesco Lo-Coco, MD, Pau Montesinos, David Grimwade, PhD, Lionel Ades, Bhuvan Kishore, Maria Pagoni, Safaa M. Ramadan, Massimo Breccia, MD, Alexandra Holowiecka, Anne Pradel, Maria Cristina Sauerland, Pierre Fenaux, MD, PhD, Miguel Angel Sanz

Blood (2010) 116 (21): 15.

https://doi.org/10.1182/blood.V116.21.15.15

Published: 2010

NARROW

Integration of Targeted Gene Expression Profiling and FDG-PET Radiomics Uncovers Radiometabolic Signatures Associated with Outcome in Diffuse Large B-Cell Lymphoma

Follicular Lymphoma Microenvironment Signatures Define Patients Subsets Obtaining Long Term Clinical Benefit after Single-Agent First-Line Anti-CD20 Immunotherapy

B-ALL/NHL 2002 GMALL Protocol As First-Line Treatment in Patients with Double-Hit Lymphoma: Favorable Results in18 Consecutive Patients from Two Italian Institutions

Prognostic Impact of the Baseline Immunologic Profile in Patients with Aggressive B Non-Hodgkin Lymphomas

Clofarabine in Combination with a Standard Remission Induction Regimen in Patients 18-60 Years Old with Previously Untreated Intermediate and Bad Risk Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS): Combined Phase I/II Results of the EORTC/Gimema AML-14A Trial

Survival Improvement Of Secondary Acute Myeloid Leukemia Over Time: Experience From 962 Patients Included In 13 EORTC-Gimema-HOVON Leukemia Group Trials

Treatment of Molecular and Clinical Relapse of Acute Promyelocytic Leukemia (APL) with Arsenic Trioxide: Results of the European Registry of Relapsed APL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only